Simplifying Global Compliance
FTC: Patent Deals Need Not Involve Overt Payments to Be Anticompetitive
Patent settlements that involve a branded company’s commitment to not launch an authorized generic (AG) in competition with a generic company (no-AG agreements) are “without a doubt” anticompetitive pay-for-delay deals even though no cash payments are involved, the FTC says in an amicus brief.
To View This Article:
Subscribe To Generic Line
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing